These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25546784)

  • 21. IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris.
    Bystryn JC; Jiao D
    Autoimmunity; 2006 Nov; 39(7):601-7. PubMed ID: 17101504
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 7th International Immunoglobulin Conference: Mechanisms of action.
    Basta M; Branch DR
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):111. PubMed ID: 25546783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective.
    Sibéril S; Elluru S; Graff-Dubois S; Negi VS; Delignat S; Mouthon L; Lacroix-Desmazes S; Kazatchkine MD; Bayry J; Kaveri SV
    Ann N Y Acad Sci; 2007 Sep; 1110():497-506. PubMed ID: 17911465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris.
    Mimouni D; Blank M; Ashkenazi L; Milner Y; Frusic-Zlotkin M; Anhalt GJ; David M; Shoenfeld Y
    Clin Exp Immunol; 2005 Dec; 142(3):426-32. PubMed ID: 16297153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 7th International Immunoglobulin Conference: Mechanisms of action.
    Basta M; Branch DR
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):87-8. PubMed ID: 25546774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus.
    Czernik A; Beutner EH; Bystryn JC
    J Am Acad Dermatol; 2008 May; 58(5):796-801. PubMed ID: 18423257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases.
    Ishii N; Hashimoto T; Zillikens D; Ludwig RJ
    Clin Rev Allergy Immunol; 2010 Apr; 38(2-3):186-95. PubMed ID: 19557317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous immunoglobulin G in the treatment of autoimmune bullous disease.
    Czernik A
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):118-9. PubMed ID: 25546786
    [No Abstract]   [Full Text] [Related]  

  • 29. What's new in i.v. immunoglobulin therapy and pemphigus: high-dose i.v. immunoglobulin therapy and its mode of action for treatment of pemphigus.
    Aoyama Y
    J Dermatol; 2010 Mar; 37(3):239-45. PubMed ID: 20507387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders.
    Emmi L; Chiarini F
    Neurol Sci; 2002 Apr; 23 Suppl 1():S1-8. PubMed ID: 12032582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin.
    Ephrem A; Misra N; Hassan G; Dasgupta S; Delignat S; Duong Van Huyen JP; Chamat S; Prost F; Lacroix-Desmazes S; Kavery SV; Kazatchkine MD
    Clin Exp Med; 2005 Dec; 5(4):135-40. PubMed ID: 16362793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Mechanisms of action of intravenous immunoglobulins in the treatment of autoimmune diseases].
    Mouthon L; Hurez V; Kazatchkine M
    Ann Med Interne (Paris); 1993; 144(8):506-13. PubMed ID: 8179238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B cells are resistant to immunomodulation by 'IVIg-educated' dendritic cells.
    Maddur MS; Hegde P; Sharma M; Kaveri SV; Bayry J
    Autoimmun Rev; 2011 Dec; 11(2):154-6. PubMed ID: 21864723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patients with bullous pemphigoid and linear IgA disease show a dual IgA and IgG autoimmune response to BP180.
    Kromminga A; Scheckenbach C; Georgi M; Hagel C; Arndt R; Christophers E; Bröcker EB; Zillikens D
    J Autoimmun; 2000 Nov; 15(3):293-300. PubMed ID: 11040070
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies.
    von Gunten S; Vogel M; Schaub A; Stadler BM; Miescher S; Crocker PR; Simon HU
    J Allergy Clin Immunol; 2007 Apr; 119(4):1005-11. PubMed ID: 17337295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunoglobulin A antibodies against desmoglein 1, envoplakin, periplakin and BP230 in a patient with atypical bullous pemphigoid.
    Yamaki F; Mayuzumi N; Ikeda S; Hashimoto T
    J Dermatol; 2010 Mar; 37(3):255-8. PubMed ID: 20507390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms of action of intravenous immunoglobulins.
    Baerenwaldt A; Biburger M; Nimmerjahn F
    Expert Rev Clin Immunol; 2010 May; 6(3):425-34. PubMed ID: 20441428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of autoimmune diseases and systemic vasculitis with pooled human intravenous immune globulin.
    Jordan SC; Toyoda M
    Clin Exp Immunol; 1994 Jul; 97 Suppl 1(Suppl 1):31-8. PubMed ID: 8033432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: a retrospective review of Mayo Clinic experience.
    Wetter DA; Davis MD; Yiannias JA; Gibson LE; Dahl MV; el-Azhary RA; Bruce AJ; Lookingbill DP; Ahmed I; Schroeter AL; Pittelkow MR
    Mayo Clin Proc; 2005 Jan; 80(1):41-7. PubMed ID: 15667028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Natural autoantibodies to TCR public idiotopes: potential roles in immunomodulation.
    Schluter SF; Adelman MK; Taneja V; David C; Yocum DE; Marchalonis JJ
    Cell Mol Biol (Noisy-le-grand); 2003 Mar; 49(2):193-207. PubMed ID: 12887102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.